CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses selinexor (Xpovio) 100 mg orally. Indication: Proposed: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy.
No takes yet. Share an insight, caveat, or question.
CADTH (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: